Your browser doesn't support javascript.
loading
CBP-HSF2 structural and functional interplay in Rubinstein-Taybi neurodevelopmental disorder.
de Thonel, Aurélie; Ahlskog, Johanna K; Daupin, Kevin; Dubreuil, Véronique; Berthelet, Jérémy; Chaput, Carole; Pires, Geoffrey; Leonetti, Camille; Abane, Ryma; Barris, Lluís Cordón; Leray, Isabelle; Aalto, Anna L; Naceri, Sarah; Cordonnier, Marine; Benasolo, Carène; Sanial, Matthieu; Duchateau, Agathe; Vihervaara, Anniina; Puustinen, Mikael C; Miozzo, Federico; Fergelot, Patricia; Lebigot, Élise; Verloes, Alain; Gressens, Pierre; Lacombe, Didier; Gobbo, Jessica; Garrido, Carmen; Westerheide, Sandy D; David, Laurent; Petitjean, Michel; Taboureau, Olivier; Rodrigues-Lima, Fernando; Passemard, Sandrine; Sabéran-Djoneidi, Délara; Nguyen, Laurent; Lancaster, Madeline; Sistonen, Lea; Mezger, Valérie.
Afiliação
  • de Thonel A; Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France. aurelie.dethonel@univ-paris-diderot.fr.
  • Ahlskog JK; Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland.
  • Daupin K; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
  • Dubreuil V; Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.
  • Berthelet J; Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.
  • Chaput C; Université de Paris, CNRS, Unité de Biologie Fonctionnelle et Adaptative, Paris, France.
  • Pires G; Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.
  • Leonetti C; Ksilink, Strasbourg, France.
  • Abane R; Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.
  • Barris LC; Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.
  • Leray I; Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.
  • Aalto AL; Laboratory of Molecular Regulation of Neurogenesis, GIGA-Stem Cells and GIGA-Neurosciences, Interdisciplinary Cluster for Applied Genoproteomics (GIGA-R), University of Liège, CHU Sart Tilman, Liège, Belgium.
  • Naceri S; Université de Nantes, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, F-44000, Nantes, France.
  • Cordonnier M; Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland.
  • Benasolo C; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
  • Sanial M; Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.
  • Duchateau A; INSERM, UMR1231, Laboratoire d'Excellence LipSTIC, Dijon, France.
  • Vihervaara A; University of Bourgogne Franche-Comté, Dijon, France.
  • Puustinen MC; Département d'Oncologie médicale, Centre Georges-François Leclerc, Dijon, France.
  • Miozzo F; Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.
  • Fergelot P; CNRS, UMR 7592 Institut Jacques Monod, F-75205, Paris, France.
  • Lebigot É; Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.
  • Verloes A; Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland.
  • Gressens P; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
  • Lacombe D; KTH Royal Institute of Technology, Stockholm, Sweden.
  • Gobbo J; Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland.
  • Garrido C; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
  • Westerheide SD; Université de Paris, CNRS, Epigenetics and Cell Fate, F-75013, Paris, France.
  • David L; Neuroscience Institute-CNR (IN-CNR), Milan, Italy.
  • Petitjean M; Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France and INSERM U1211, University of Bordeaux, Bordeaux, France.
  • Taboureau O; Service de Biochimie-pharmaco-toxicologie, Hôpital Bicêtre, Hopitaux Universitaires Paris-Sud, 94270 Le Kremlin Bicêtre, Paris-Sud, France.
  • Rodrigues-Lima F; Université de Paris, INSERM, NeuroDiderot, Robert-Debré Hospital, F-75019, Paris, France.
  • Passemard S; Genetics Department, AP-HP, Robert-Debré University Hospital, Paris, France.
  • Sabéran-Djoneidi D; Université de Paris, INSERM, NeuroDiderot, Robert-Debré Hospital, F-75019, Paris, France.
  • Nguyen L; Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France and INSERM U1211, University of Bordeaux, Bordeaux, France.
  • Lancaster M; INSERM, UMR1231, Laboratoire d'Excellence LipSTIC, Dijon, France.
  • Sistonen L; University of Bourgogne Franche-Comté, Dijon, France.
  • Mezger V; Département d'Oncologie médicale, Centre Georges-François Leclerc, Dijon, France.
Nat Commun ; 13(1): 7002, 2022 11 16.
Article em En | MEDLINE | ID: mdl-36385105
ABSTRACT
Patients carrying autosomal dominant mutations in the histone/lysine acetyl transferases CBP or EP300 develop a neurodevelopmental disorder Rubinstein-Taybi syndrome (RSTS). The biological pathways underlying these neurodevelopmental defects remain elusive. Here, we unravel the contribution of a stress-responsive pathway to RSTS. We characterize the structural and functional interaction between CBP/EP300 and heat-shock factor 2 (HSF2), a tuner of brain cortical development and major player in prenatal stress responses in the neocortex CBP/EP300 acetylates HSF2, leading to the stabilization of the HSF2 protein. Consequently, RSTS patient-derived primary cells show decreased levels of HSF2 and HSF2-dependent alteration in their repertoire of molecular chaperones and stress response. Moreover, we unravel a CBP/EP300-HSF2-N-cadherin cascade that is also active in neurodevelopmental contexts, and show that its deregulation disturbs neuroepithelial integrity in 2D and 3D organoid models of cerebral development, generated from RSTS patient-derived iPSC cells, providing a molecular reading key for this complex pathology.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Rubinstein-Taybi / Fatores de Transcrição / Proteína de Ligação a CREB / Transtornos do Neurodesenvolvimento / Proteínas de Choque Térmico Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Rubinstein-Taybi / Fatores de Transcrição / Proteína de Ligação a CREB / Transtornos do Neurodesenvolvimento / Proteínas de Choque Térmico Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França